DSGN - Company ID 0001807120
The table below shows Design Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | - | - | $0.00 | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $14.38M | $14.59M | $15.74M | $15.38M | $11.88M | $10.52M |
| SG&A |
Design Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $5.33M |
| $4.72M |
| $5.83M |
| $5.04M |
| $4.37M |
| $4.53M |
| Operating income | -$19.71M | -$19.31M | -$21.57M | -$20.42M | -$16.25M | -$15.04M |
| Income tax | - | - | - | - | - | - |
| Net income | -$17.64M | -$17.00M | -$19.08M | -$17.71M | -$13.04M | -$11.79M |
| EPS (diluted) | -$0.29 | -$0.30 | -$0.34 | -$0.31 | -$0.23 | -$0.21 |